

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2008 (24.04.2008)

PCT

(10) International Publication Number
WO 2008/046598 A1

(51) International Patent Classification:

C07D 215/22 (2006.01) A61P 9/00 (2006.01)
C07C 217/60 (2006.01) A61P 11/06 (2006.01)
A61K 31/435 (2006.01) A61P 29/00 (2006.01)
A61K 31/137 (2006.01) A61P 27/06 (2006.01)

(21) International Application Number:

PCT/EP2007/008992

(22) International Filing Date: 17 October 2007 (17.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

P200602676 20 October 2006 (20.10.2006) ES

(71) Applicant (for all designated States except US): **LABORATORIOS ALMIRALL, S.A.** [ES/ES]; Ronda del General Mitre, 151, E-08022 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACH TANA, Jordi** [ES/ES]; Avenida MS Salarich I Torrents, Bajos 1a, E-08500 Vic (ES). **CRESPO CRESPO, Maria, Isabel** [ES/ES]; C/comte d'Urgell 259, 6^a 3^a, E-08036 Barcelona (ES). **PUIG DURAN, Carlos** [ES/ES]; C/Asturias 93,

2^o 2^a, E-08024 Barcelona (ES). **GUAL ROIG, Silvia** [ES/ES]; c/d'En Majó 2, Esc. E 4^o 2^a, E-08349 Cabrera de Mar (ES). **ORTEGA MUÑOZ, Albert** [ES/ES]; Pasaje Caralt 16, 1^o 3a, 08924 Santa Coloma de Gramanet, Barcelona (ES).



(74) Agents: **SRINIVASAN, Ravi, Chandran et al.**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β_2 ADRENERGIC RECEPTOR



(57) Abstract: The present invention provides a Compound of formula (I), wherein: R^1 is a group selected from $-\text{CH}_2\text{OH}$, $-\text{NH}(\text{CO})\text{H}$; and R^2 is a hydrogen atom; or R^1 together with R^2 form the group $-\text{NH}-\text{C}(\text{O})-\text{CH}=\text{CH}-$, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R^1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R^2 ; R^{3a} and R^{3b} are independently selected from the group consisting of hydrogen atoms and C_{1-4} alkyl groups; X and Y are independently selected from the group consisting of direct bond and oxygen atom; n, m and q each independently has a value selected from 0, 1, 2 and 3; p has a value selected from 1, 2 and 3; R^4 and R^5 are independently selected from hydrogen atoms, halogen atoms, C_{1-4} alkyl, C_{1-4} alkoxy, $-\text{CONH}_2$, $-\text{NHCONH}_2$, $-\text{SR}^7$, $-\text{SOR}^7$, $-\text{SO}_2\text{R}^7$, $-\text{SO}_2\text{NHR}^8$ and the groups (a) and (b), wherein R^7 is selected from C_{1-4} alkyl and C_{3-8} cycloalkyl and R^8 is selected from hydrogen atoms and C_{1-4} alkyl groups; R^6 is selected from the group consisting of hydrogen atoms, halogen atoms, C_{1-4} alkyl and C_{1-4} alkoxy or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*